Press "Enter" to skip to content

Tag: research

‘I couldn’t breathe’: the deadly health burden of wildfire smoke

Scientists race to untangle complex links between exposure and mortality as fire weather grows more prevalent

A thousand kilometres from the infernos gorging on northern Ontario’s boreal forests, Erin O’Connor watched the sky above Canada’s biggest city turn an “almost post-apocalyptic” orange as it filled with light-scattering particles of soot and ash. Stepping outside the halls of Toronto General hospital, where air filters were keeping patients safe from the worst of the fumes, she was struck by a smell so strong it felt like standing by a campfire.

“It really hit you in the face as soon as you walked outside,” said O’Connor, who runs University Health Network’s emergency department and saw a rise in patients presenting with allergies and shortness of breath. “As the days progressed, it was like that everywhere. It seemed even inside you could smell that burning.”

Far more than the flames that have engulfed southern Europe and North America in recent weeks, it is the smoke that dominates the astonishing death toll from combusting nature. Thick with toxic gases that inflame the airways and tiny particulates that breach the lungs and ride the bloodstream to hit every organ in the body, fumes from landscape fires kill 1.5 million people each year, a study in the Lancet found in 2024 – more than floods, flames, storms and heat combined.

Comments closed

New Study Provides First Evidence of Dopamine System Injury in the Brain of Long COVID Patients

Findings have important implications for the pathophysiology of key COVID symptoms and suggest new potential avenues for treatment

Toronto, ON (July 10, 2026) — A new brain imaging study led by researchers at the Centre for Addiction and Mental Health (CAMH), published in eBioMedicine, provides the strongest evidence to date that long COVID is associated with injury to dopamine-releasing neurons in the brain—a finding that may explain symptoms such as lack of motivation due to fatigue, slowed movement, and memory difficulties, and could open the door to new treatment strategies.

Long COVID is estimated to affect five per cent of the world population, including two million Canadians, and is characterized by a wide range of persistent and sometimes debilitating symptoms, including brain-related ones such as fatigue, brain fog, memory problems, or low mood, that continue for at least three months following the initial COVID-19 infection. Despite its prevalence, no evidence-based treatments currently exist, largely due to limited understanding of the underlying brain pathology.

In the new study, researchers used positron emission tomography (PET) brain imaging to measure a well-established marker of dopamine neuron integrity in people with long COVID and healthy individuals.

Comments closed

Buildings May Soon Have ‘Immune Systems’ That Fight Airborne Disease

Following the pandemic, the federal government is spending $150 million on new technology to ensure clean indoor air. Here’s what scientists are pursuing.

Linsey Marr, an environmental engineer, stood next to a pair of clear plastic boxes packed with tubes, nozzles and electronics, an odd-looking prototype that one day might serve to protect children in day care from airborne pathogens.

A nozzle filled the right-hand box with a faint silvery mist. A pump pulled some of that air into the left-hand box, where a sampler trapped floating particles and droplets. Soon, a digital screen bolted to the box turned red: “Detected! Dust mite allergen Der f 1.”

A protein shed by dust mites, Der f 1 can trigger asthma attacks when inhaled. Dr. Marr’s device had detected 843 picograms of Der f 1 per cubic meter. A single grain of salt is about 10 million times as heavy.

Comments closed

Long COVID may affect 1 in 6 infected patients

Long COVID may be affecting far more Americans than current estimates suggest, with a study published last week in JAMA Network Open estimating that roughly one in six people infected with SARS-CoV-2 develop the condition, and nearly 90% go on to experience chronic health problems.

For the study, a team led by researchers at Massachusetts General Hospital analyzed health record data from 457,950 adults treated for COVID-19 (also known as postacute sequelae of SARS-CoV-2 infection, or PASC) across 58 hospitals and clinics in New England, Southeast Texas, Southern California, and Western Pennsylvania.

The researchers identified long COVID cases by detecting symptoms and conditions that emerged after infection and could not be explained by preexisting conditions.

Comments closed

Seasonal COVID-19 vaccination in 2025/26 reduced risk of illness by half in Canada

An interim analysis published in Eurosurveillance estimates that the COVID-19 vaccine for the 2025/26 season reduced the risk of illness in Canada by about half at about 9 weeks after vaccination, offering protection beyond the vaccine’s target strain.

Seasonal COVID-19 vaccination is recommended in Canada as in several other countries for people older than 6 months with an increased risk of severe illness from the infection, and for all adults aged 65 or older. In the 2025/26 respiratory virus season, the vaccine was updated to target the LP.8.1 strain as recommended by the World Health Organization (WHO), but other strains were also circulating during that period.

Comments closed

HHS rejects publication of study showing Covid-19 vaccines prevent hospitalizations, ER visits

Covid-19 vaccines roughly halved the chances that a US adult would need to visit the emergency room or be hospitalized with their infections last fall and winter, according to two sources familiar with the findings of a new study. But you won’t hear about it from the agency that led the research: the US Centers for Disease Control and Prevention.

The current head of the CDC, Dr. Jay Bhattacharya, who’s also director of the US National Institutes of Health, blocked the publication of those findings in the CDC’s flagship journal, the Morbidity and Mortality Weekly Report, according to the sources.

The authors of the study received an official rejection letter from the journal on Tuesday, one source said, even though the study had cleared internal reviews and had been scheduled for publication.

Comments closed

Common antidepressant can treat long COVID fatigue symptoms: study

A common and low-cost antidepressant can successfully treat fatigue associated with long COVID, according to a new study.

Co-led by researchers from McMaster University in Ontario, the study found that the drug fluvoxamine, which is commonly sold under the name Luvox, significantly reduced fatigue symptoms in a clinical trial of 399 adults with long COVID. It is one of the first times a medication has been shown to effectively treat the condition.

“This is an important step forward for patients who have been desperate for evidence‑based options,” senior author and McMaster University professor Edward Mills said in a news release.

Comments closed

Study: SARS-CoV-2 RNA found in 39% of hospital air samples during outbreaks, despite good ventilation

COVID-19 genetic material was frequently detected in hospital air during community outbreaks, even in well-ventilated settings, according to a new study published in Respiratory Medicine.

A team led by Kirby Institute researchers conducted air and surface sampling in the emergency department (ED) and intensive care unit (ICU) of a large metropolitan hospital in Sydney, Australia, during two COVID-19 waves between November 2023 and July 2024. Their testing found that 39% (20 of 51) of aerosol samples were positive for SARS-CoV-2 RNA.

Detection was significantly more common in the ED than in the ICU. Of the positive samples, 80% were collected in the ED and 20% in the ICU.

Comments closed

The Secret Weapon in Canada’s Sewers

As America takes an axe to its health data, expanding wastewater surveillance could save lives

As a virologist, I spend my days thinking about how to detect outbreaks of coronaviruses, mpox, West Nile and other pathogens early enough to stop them. Right now, I’m concerned about Canada’s awful flu season and the fact that we recently lost our measles-elimination status. But mostly, I’m terrified of what’s unfolding south of the border.

The consequences of the Trump administration’s cuts to the CDC and NIH will extend far beyond America. Those agencies form the backbone of North America’s infectious-disease surveillance. They track variants, monitor cross-border spread and feed data into global systems coordinated by the World Health Organization, helping everyone on Earth prepare. When those programs are dismantled, Canada loses key warning signs of influenza, RSV, measles and whatever diseases are coming next.

Comments closed

This year’s Pfizer COVID vaccine estimated to be 57% effective against emergency, urgent care

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% effective against outpatient visits among adults roughly 4 weeks after vaccination, with considerable uncertainty, according to preliminary estimates published on the preprint server medRxiv.

A team that included researchers from the Providence Veterans Affairs (VA) Healthcare System and Pfizer used a test-negative case-control design to estimate the early vaccine effectiveness (VE) of Pfizer’s BNT162b2 LP.8.1 vaccine against ED/UC and outpatient visits.

Participants were VA patients who had an acute respiratory infection (ARI) and underwent COVID-19 testing from September 10 to November 30, 2025.

Comments closed

Could the shingles vaccine prevent or delay new-onset dementia? Ontario-based study suggests so

A new Ontario-based study is suggesting the shingles vaccine may help prevent and/or delay the onset of dementia more effectively than any existing treatment.

The study was published in Lancet Neurology and led by researchers at McMaster University and Stanford University. It analyzed health data from more than 250,000 seniors in Ontario and found the herpes zoster vaccination, also known as the shingles vaccine, helped significantly prevent dementia.

“There’s no pharmacological tool that has been shown to have such a large preventative effect,” Pascal Geldsetzer, lead researcher and Stanford University professor, told CTV News Toronto.

Comments closed

Post-COVID Brain Fog Linked to Elevated pTau-181

NEW evidence from a prospective cohort study suggests that elevated plasma phosphorylated tau (pTau-181) may be a critical biomarker in patients experiencing neurological post-acute sequelae of COVID-19 (N-PASC), particularly among essential workers.

Comments closed

Increased levels of Alzheimer’s-linked protein found in some with long COVID

A study of 227 individuals who experienced neurocognitive difficulties post COVID-19 infection—such as headaches, vertigo, balance dysregulation, changes in taste/smell, and brain fog—displayed a significant increase in their blood plasma of a crucial protein called tau, which is found in nerves and especially in the brain. Excess levels of tau are linked to neurodegenerative diseases and found in many Alzheimer’s patients.

Published in eBioMedicine, the study suggests that people who experience long COVID neurocognitive symptoms could be at further risk for neurodegenerative diseases.

Comments closed

Moderna COVID vaccine 53% effective against adult hospitalization in 2024-25 season, data suggest

A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024-25 COVID vaccine was 39% effective at preventing medically attended illness among adults and 53% effective against hospitalization, particularly those at high risk for severe disease.

The study, led by scientists from the vaccine manufacturer and published late last week in Infectious Diseases and Therapy, analyzed outcomes among 596,248 adults who received the updated mRNA-1273 vaccine, which targeted the Omicron KP.2 variant, from August 2024 to April 2025. Vaccinated people were matched 1:1 with unvaccinated counterparts.

Comments closed

In utero COVID exposure linked to brain changes, developmental delays, anxiety, and depression

In utero SARS-CoV-2 exposure may predispose children to altered brain volumes, impaired cognition, and internalizing emotional problems such as anxiety and depression, researchers from Children’s National Hospital and George Washington University write in Brain, Behavior, and Immunity.

The team enrolled 39 mother-baby pairs in Washington, DC, who had been exposed to COVID-19 during pregnancy from 2020 to 2022 and compared them with 103 normative pairs from before the pandemic (2016 to 2019). None of the infected women had been vaccinated against SARS-CoV-2.

Comments closed

Lyme disease research at Johns Hopkins in jeopardy due to federal funding delays

MARYLAND (WJZ) — Maryland has some of the highest cases of Lyme disease in the nation, yet funding for research is in jeopardy.

Lyme disease is the most common and fastest-growing vector-borne disease in the United States. Approximately 476,000 Americans are diagnosed and treated for it each year, according to the Centres for Disease Control and Prevention (CDC).

In Maryland, Lyme disease cases have nearly doubled since 2020, according to the latest data from the Maryland Department of Health.

Comments closed

Workplace exposures tied to higher risk of long COVID

Work-related factors may increase the risk of developing long COVID, according to a new population-based study from Spain.

The findings, published in BMJ Occupational & Environmental Medicine, suggest that the primary work-related drivers of increased long COVID risk were irregular or limited use of respirators, close contact with coworkers and/or the public, inability to physical distance, and use of public transportation to commute to work.

Comments closed